MetLife Investment Management, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$148,161
-22.7%
4,156
+0.0%
0.00%0.0%
Q2 2023$191,624
+38.3%
4,154
+20.2%
0.00%0.0%
Q1 2023$138,586
-13.2%
3,456
+0.2%
0.00%0.0%
Q4 2022$159,746
+9.3%
3,448
-2.3%
0.00%0.0%
Q3 2022$146,177
-30.7%
3,530
-0.1%
0.00%
-50.0%
Q2 2022$210,838
-16.3%
3,534
+1.9%
0.00%0.0%
Q1 2022$251,774
-90.6%
3,467
-85.3%
0.00%
-92.0%
Q1 2021$2,681,403
-22.2%
23,550
-5.4%
0.02%
-28.6%
Q4 2020$3,444,415
+75.4%
24,882
+4.2%
0.04%
+59.1%
Q3 2020$1,963,355
+0.6%
23,888
-4.3%
0.02%0.0%
Q2 2020$1,952,137
+92.2%
24,957
+9.2%
0.02%
+57.1%
Q1 2020$1,015,448
-2.8%
22,855
-6.6%
0.01%
+27.3%
Q4 2019$1,044,772
-0.2%
24,4620.0%0.01%
-8.3%
Q3 2019$1,046,484
-32.6%
24,4620.0%0.01%
-29.4%
Q2 2019$1,553,335
+0.4%
24,462
+9.7%
0.02%0.0%
Q1 2019$1,546,451
+75.8%
22,296
+10.2%
0.02%
+54.5%
Q4 2018$879,470
-43.0%
20,2270.0%0.01%
-31.2%
Q3 2018$1,544,129
-6.6%
20,227
-5.9%
0.02%
-20.0%
Q2 2018$1,653,000
+61.1%
21,505
+6.9%
0.02%
+66.7%
Q1 2018$1,026,000
+20.8%
20,122
+9.9%
0.01%
+20.0%
Q4 2017$849,00018,3150.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2023
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 727,426$25,932,7374.72%
RTW INVESTMENTS, LP 5,405,089$192,691,4234.07%
First Light Asset Management, LLC 1,125,032$40,107,3913.81%
CHI Advisors LLC 215,000$7,664,7503.04%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 250,052$8,914,3543.00%
SPHERA FUNDS MANAGEMENT LTD. 259,135$9,238,1631.68%
Rock Springs Capital Management LP 1,476,441$52,635,1221.41%
SUVRETTA CAPITAL MANAGEMENT, LLC 679,459$24,222,7131.31%
Privium Fund Management B.V. 115,241$4,108,3411.22%
SECTOR GAMMA AS 115,166$4,105,6681.05%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders